Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematologic malignancies.

M Petryk1, M L Grossbard

  • 1St. Luke's-Roosevelt Hospital Center, New York, New York 10019, USA.

The Oncologist
|August 29, 2001
PubMed
Summary

New targeted therapies, including radioimmunoconjugates (RICs) and fusion toxins, show promise for hematologic malignancies like non-Hodgkin's lymphoma and hairy cell leukemia, advancing cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chiral, triformylphenol-derived salen-type [4 + 6] organic cages.

Organic & biomolecular chemistry·2016
Same author

An array of virtual Frisch-grid CdZnTe detectors and a front-end application-specific integrated circuit for large-area position-sensitive gamma-ray cameras.

The Review of scientific instruments·2015
Same author

131I tositumomab: a viewpoint by Michael L. Grossbard.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Leukemia & lymphoma·2005
Same author

Pancreatic carcinoma with brain metastases: case report and literature review.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2004
Same author

Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.

Anti-cancer drugs·2004

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Advances in understanding tumor immunology and molecular biology are driving the development of novel therapies for hematologic malignancies.
  • Targeted therapies are transitioning from research to clinical application.

Purpose of the Study:

  • To review key findings in hematologic malignancies presented at the 2001 American Society of Clinical Oncology meeting.
  • To highlight the progress of targeted therapies, particularly monoclonal antibody-based treatments.

Main Methods:

  • Review of data presented on radioimmunoconjugates (RICs) such as tositumomab and Iodine 131 tositumomab (Bexxar) and ibritumomab tiuxetan (Zevalin).
  • Evaluation of a novel fusion toxin, BL22, targeting the CD22 antigen.
  • Assessment of the Hu1D10 monoclonal antibody for B-cell non-Hodgkin's lymphoma (NHL).
  • Review of advances in mucositis treatment.

Main Results:

  • RICs demonstrated high response rates in relapsed B-cell NHL.
  • The first trial comparing an RIC (Zevalin) to an unconjugated antibody (rituximab) was presented.
  • A new application of RIC therapy in high-dose treatment for mantle cell NHL was described.
  • BL22 showed significant activity in treating hairy cell leukemia.
  • Hu1D10 monoclonal antibody exhibited activity in B-cell NHL.

Conclusions:

  • Monoclonal antibody-based therapies, including RICs, are a significant advancement in treating hematologic malignancies.
  • Targeted therapies derived from enhanced understanding of tumor immunology and molecular biology offer new treatment avenues.
  • Further research and clinical trials are warranted to optimize these novel therapeutic strategies.

Related Experiment Videos